Mike Hollan

It’s unclear what direction the company will take based on how events unfolded after its last presentation.

If previous conference presentations are any indication, Merck will likely detail its plans to broaden its pipeline ahead of 2028.

The pharma giant will likely announce its acquisition plans for the coming year at the healthcare conference.

AbbVie has spent previous conferences detailing its work to rebuild its pipeline after losing Humira patent protection.

Pharmaceutical Executive detail’s the company’s history at the healthcare conference.

Ahead of the healthcare conference in January, Pharmaceutical Executive takes a look back at Novartis’ history at the conference.

The investment will allow the facility to meet the growing demand for RNAi therapeutics.

Nine more companies have joined the DTC government-run website, which is set to launch sometime next year.

The bill was part of the larger Defense Bill and will impact funding available to certain foreign companies.

The representatives from Pennsylvania and New York, joined with Democrats to force a vote on legislation against Speaker Johnson’s wishes.

In the third and final part of her conversation with Pharmaceutical Executive, discusses the ways that regulatory agencies in major global markets are acting in similar ways to have a positive impact on the biosimilars market.

Experts weigh in on FDA’s new accelerated review program, revealing what companies stand to benefit the most from the initiative.

Amid the US reshoring push, drugmakers navigate geopolitical and supply chain risks.

Will the politically fueled reforms and mandates around drug pricing reduce the complexity of the system?

The deal will provide Zealand with access to OTR’s proprietary R&D platform.

In the second part of her conversation with Pharmaceutical Executive, Gillian Woollett, VP and head of regulatory strategy at Samsung Bioepis, explains the direct impact changes at FDA have on the biosimilar space.

Gillian Woollett, VP and head of regulatory strategy at Samsung Bioepis, discusses how the current regulatory climate is the result of years of work.

The Lifescience Dynamics analyst discusses how GLP-1s appear to provide kidney protection in a specific, well-defined population.

In the final part of this conversation, Dr. Bruce Leuchter, CEO of Neurvati Neurosciences, discusses new programs at FDA and how the neuroscience space is benefitting.

Jay Bregman, co-founder of Andel, closes out our conversation by explaining the impact government programs will have on GLP-1 coverage.

Dr. Bruce Leuchter, CEO of Neurvati Neurosciences, explains why psychedelics continues to be an area of interest.

Dr. Bruce Leuchter, CEO of Neurvati Neurosciences, continues his conversation, this time looking to the upcoming year in neuroscience.

In the final part of our conversation with Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, he discusses how FDA’s new program may or may not impact manufacturing pipelines.

New technologies are helping the industry move toward more predictive and humane approaches.

In the second part of our conversation, Andel co-founder Jay Bregman how new GLP-1 options hitting the market will amplify existing coverage problems for the near future.

In the first part of this video, Dr. Bruce Leuchter, CEO of Neurvati Neuroscience, discusses which areas of neuroscience are exciting investors.

Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, continues his conversation about FDA’s Priority Review Voucher Program, and explains what the industry can learn from the announced participants.

Jay Bregman, co-founder of Andel, the cost and operational complexity of covering GLP-1 medications.

In the first part of our conversation with Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, he provides a broad overview of the possible positive and negative impacts of FDA’s Priority Review Voucher Program.

Craig Ackerman, partner in the Alexander Group and lead of its medical device practice, discusses how AI is being used and whether pharma companies should brace for the bubble to pop.